Related Experiment Videos
Update on therapy for refractory dermatomyositis and polymyositis
1National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Arthritis and Rheumatism Branch, Bethesda, MD 20892-1820, USA.
Current Opinion in Rheumatology
|November 1, 1996
Summary
Treating inflammatory myopathies requires early rehabilitation and a stepwise approach. Consider second-line agents or pulse steroids early due to corticosteroid side effects and disease heterogeneity.
Area of Science:
- Rheumatology
- Neurology
- Immunology
Background:
- Inflammatory myopathies present diagnostic and therapeutic challenges due to heterogeneity.
- Lack of standardized definitions for disease categories, activity, and chronicity complicates evaluation.
- Current treatment guidelines require refinement for optimal patient outcomes.
Purpose of the Study:
- To review current therapeutic strategies for inflammatory myopathies.
- To emphasize the importance of early rehabilitation in managing these conditions.
- To propose a stepwise progression of treatment based on disease activity and severity.
Main Methods:
- Literature review of existing therapeutic options for inflammatory myopathies.
- Analysis of the efficacy and side effect profiles of common treatments.
- Expert opinion on the integration of rehabilitation and pharmacotherapy.
Main Results:
- Oral corticosteroids are the primary treatment but have significant side effects.
- A subset of patients requires high-dose corticosteroids, necessitating alternative strategies.
- Early introduction of immunomodulating agents or pulse methylprednisolone is recommended for refractory cases.
Conclusions:
- A proactive, stepwise therapeutic approach is crucial for managing inflammatory myopathies.
- Early rehabilitation evaluation should be integrated into the management plan.
- Tailoring treatment strategies based on individual patient needs and disease progression is essential for improving outcomes.